GSK (LON:GSK) Stock: Insider Julie Brown Buys 7 Shares

GSK plc (LON:GSK) insider Julie Brown acquired 7 shares of the company’s stock in a transaction that occurred on Friday, October 9th. The shares were bought at an average price of GBX 1,765 per share, for a total transaction of £123.55.

Julie Brown also recently made the following trade(s):

• On Wednesday, September 9th, Julie Brown acquired 7 shares of GSK stock. The stock was bought at an average cost of GBX 1,803 per share, for a total transaction of £126.21.

GSK Trading Down 0.9%

GSK opened at GBX 1,754.78 on Wednesday. The stock has a market capitalization of £70.31 billion, a P/E ratio of 14.90, a P/E/G ratio of 1.24 and a beta of 0.29. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. GSK plc has a 12 month low of GBX 1,592 and a 12 month high of GBX 2,282. The firm’s fifty day simple moving average is GBX 1,852.43 and its 200 day simple moving average is GBX 1,929.79.

GSK (LON:GSK) last released its earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. As a group, research analysts anticipate that GSK plc will post 175.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on GSK shares. Berenberg Bank upped their price objective on GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research report on Tuesday, September 15th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a research report on Tuesday, September 29th. Royal Bank Of Canada restated a “sector perform” rating and issued a GBX 1,975 target price on shares of GSK in a research note on Tuesday, September 8th. Finally, Jefferies Financial Group restated a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a research note on Wednesday, July 29th. Two research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of GBX 2,064.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.